KPV

Tripeptide fragment of α-MSH studied for inflammatory modulation.

Studied for melanocortin receptor signaling and intracellular anti-inflammatory effects.

Immune signaling and gut inflammation models.

Studied for, research explores, preclinical models suggest, clinical studies have investigated.

Limited public data on dosing ranges across research models.

Adverse effect data is limited. Many compounds in this database lack human safety profiles.

KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH. Research describes anti-inflammatory signaling associated with NF-κB modulation, antimicrobial activity in cell models, and broader immune-modulatory behavior in inflammatory disease models.

Sits within inflammatory signaling pathways, with reported activity at the NF-κB and innate immune signaling layer.

• Inflammatory bowel disease preclinical models
• Skin inflammation research
• Antimicrobial activity in vitro studies
• General inflammation modulation research

Mechanistic anti-inflammatory data is reasonably developed in cell and animal models, with limited controlled human outcome studies.

Human safety profile is not extensively characterized. Long-term systemic effects are not established.

Translation from animal inflammation models to human outcomes is not established.